
The companies will focus on developing therapeutics across neuroscience, immunology and oncology

The deal gives the company access to a range of central nervous system disorder drugs

The companies will advance therapeutics for undisclosed targets in Novartis’ core areas

The deal includes a candidate in phase 1 development for Alzheimer's disease

The companies will advance small molecule therapeutics against a new class of targets for cancer

The companies will focus on targets in oncology, neuroscience and inflammation

The agreement gives Novartis access to three preclinical neuroscience programmes
Yotam Drechsler (Co-founder/CEO) and Yaron Segal (Co-founder/CINO) from BrainQ Technologies dives into the roles of Brain-Computer Interface technologies and electrophysiology measurements in aiding neurorecovery, the role of AI and machine...

Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Ramsay Brown, CEO and Founder of Quol, delves into several different HealthTech topics, including the concept of VR therapeutics and the importance of incorporating behavioral science and neuroscience into VR solutions, as...
In the latest episode of Impetus Digital's Fireside Chat, we dive into the concept of merging art and science with Ariel Garten, Founder & Chief Evangelism Officer at Muse. Ariel...